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Cell Therapy for Huntington’s
Disease: Learning from Failure
We write in response to the editorial by Albin and
Kordower,1 “A Failed Future,” which offers a perspective on
the Multicentric Intracerebral Grafting in Huntington’s Dis-
ease (MIG-HD) fetal cell transplantation study in
Huntington’s disease (HD).2 Although MIG-HD did not
achieve a positive clinical outcome, Albin and Kordower’s
critique of that study provides critical points of interpretation
that we believe incorrect. In particular, we reject their cate-
gorical rejection of cell therapy as a regenerative treatment
option for HD on the basis of a single phase II study of fetal
cell transplantation. Indeed, Albin and Kordower highlight
the confounds potentially caused by protocol changes during
MIG-HD that emphasize the exploratory nature of this trial.
Cell therapy has advanced substantially since MIG-HD was
initiated; we now have fuller understanding of the cellular
phenotypes and interactions that go awry in HD and thus a
clearer understanding of cell-based strategies that might be
used in its treatment. We suggest that Albin and Kordower
make unwarranted predictions of future failure—effectively
“throwing out the baby with bath water”—based on an
overly broad interpretation of MIG-HD, leading them to a
conclusion that is neither justified nor cognizant of the cur-
rent science and does a disservice to current work in
the field.
MIG-HD focused on achieving neural circuit reconstruc-
tion through transplanting striatal precursors isolated from
fetal ganglionic eminence. It built on preclinical data and
previous pilot human studies,3 which constituted proof of
concept that transplants can improve function and that this
may not require every element of pathology to be
addressed, something borne out in Parkinson’s disease
transplant studies where pathology also exists outside the
key central nervous system target of cell therapy.4 The limi-
tations of fetal-derived donor cells stimulated research to
derive candidate therapeutic progenitors (glial as well as
neuronal5) from human pluripotent stem cells. Such cell
products vary in their intended functions and therapeutic
goals (eg, cell replacement, neuroprotection) with numerous
reports of significant functional benefits (eg, Reidling and
colleagues6). It is uninformative to lump these different
products, targets, and therapeutic aims together and mis-
leading to dismiss them all on the basis of a single phase II
study initiated 2 decades ago.
We believe a more productive approach is to formulate an
honest, comprehensive appraisal of foreseeable challenges to
develop a rational road map for moving forward. There
should be due consideration of the limitations of MIG-HD
and previous studies, leading to new perspectives on the
design and implementation of clinical trials of cell therapies
in HD (as reviewed in Bachoud-Lévi and colleagues7).
Indeed, publication and informed analysis of such negative
data are precisely how we may best ensure future success.
To facilitate this, we established Stem Cells for HD (SC4HD;
https://www.sc4hd.org/), a global consortium of experts
working in various areas of cell therapy. The group invites
external peer review and is developing evidence-based guid-
ance documents for the establishment of best practices in the
field. We believe that this is the right process by which to
assess whether the complex, but potentially powerful, strat-
egy of cell-based therapies can have a place in the treat-
ment of HD.
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Reply to: “Cell Therapy for
Huntington’s Disease: Learning
from Failure”
We are pleased that our editorial provoked discussion of
research priorities in Huntington disease (HD).1 Rosser et al, how-
ever, misrepresent our comments. Rosser et al allege a “categorical
rejection of cell therapy as a regenerative treatment option for HD
on the basis of a single phase II study of foetal cell transplanta-
tion.”2 This statement indicates that we regard MIG-HD as a
definitive test of the value of cell transplantation. As was stated
clearly in our editorial, one of our major criticisms of the MIG-
HD study is that it failed to test the efficacy of engrafting fetal tis-
sues and could not inform discussion of whether the general
approach of cell therapy for HD is appropriate. Indeed, after more
than 30 years of cell replacement strategy experiments, we were
left with a clinical trial in which no graft survival was evident.
Our skepticism about the value of cell transplantation for HD
rests on HD being a multifocal neurodegeneration and the slender
preclinical evidence base for these kinds of interventions. Rosser
et al cite Reidling et al as an example of promising preclinical data,
but the results of this work underscore our concerns.3 These were
well-executed experiments using the R6/2 transgenic fragment
and Q140 knock-in murine genetic models. R6/2 has been the test
bed for numerous potential therapies, some translated to clinical
trials, and all translated interventions without success in trials.
How does success in a model without predictive validity support
proceeding to clinical experiments? Q140 may be a better model.
The conventional but crude behavioral outcome measures
employed, however, are not likely to be informative of what hap-
pens in humans. To reinforce one of our points, regardless of the
source of cells engrafted, the benefits of grafting will have to be
substantial to compensate for the risks of surgeries. There should
be substantial and convincing preclinical evidence of benefits
before proceeding to trials. Newer therapeutic approaches
designed to address the root pathology of HD, mutant huntingtin
expression, have outpaced cell replacement therapy forHD. These
newer approaches have a far greater chance of addressing all
major symptomatic features of HD, including cognitive and
behavioral deficits. HD participants undergoing cell transplanta-
tion experiments will be ineligible for other clinical trials.
Rosser et al describe a consortium aimed at developing “best
practices in the field.” We suggest moving the focus away from
relatively narrow technical considerations to critical thinking
about the justification for these kinds of experiments.
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